CervoMed Inc (CRVO) concluded trading on Wednesday at a closing price of $6.17, with 156.41 million shares of worth about $965.04 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -61.39% during that period and on March 12, 2025 the price saw a gain of about 161.44%. Currently the company’s common shares owned by public are about 8.25M shares, out of which, 5.35M shares are available for trading.
Stock saw a price change of 185.65% in past 5 days and over the past one month there was a price change of 181.74%. Year-to-date (YTD), CRVO shares are showing a performance of 163.68% which decreased to -62.90% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.80 but also hit the highest price of $26.38 during that period. The average intraday trading volume for CervoMed Inc shares is 240.89K. The stock is currently trading 154.91% above its 20-day simple moving average (SMA20), while that difference is up 167.40% for SMA50 and it goes to -43.98% lower than SMA200.
CervoMed Inc (NASDAQ: CRVO) currently have 8.25M outstanding shares and institutions hold larger chunk of about 18.00% of that.
The stock has a current market capitalization of $50.93M and its 3Y-monthly beta is at 1.73. It has posted earnings per share of -$1.64 in the same period. It has Quick Ratio of 15.04 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CRVO, volatility over the week remained 45.81% while standing at 16.16% over the month.
Analysts are in expectations that CervoMed Inc (CRVO) stock would likely to be making an EPS of -0.63 in the current quarter, while forecast for next quarter EPS is -0.55 and it is -1.28 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.72 which is -0.38 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.95 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -125.96% while it is estimated to increase by 30.84% in next year. EPS is likely to shrink at an annualized rate of -12.42% for next 5-years, compared to annual growth of 73.43% made by the stock over the past 5-years.
Stock get a Buy rating from ROTH MKM on December 06, 2024.
